Abstract 5988
Background
Stage IV pancreatic cancer is a lethal disease. Current standard practice is combination chemotherapy such as FOLFIRINOX or Gemcitabine and Abraxane. The glycolic and mitochondrial metabolism are aberrant in pancreatic cancer and translate into chemoresistance. Inhibition of glutamine metabolism can potentially synergize with therapies that increase intracellular reactive oxygen species such as FOLFIRINOX components. CPI- 613 is a novel antimitocondrial developed by Rafael Pharmaceuticals that showed preclinical activity in pancreatic cancer.
Methods
We designed a phase 1 study to evaluate for synergy between CPI -613 and FOLFIRINOX for patients with stage IV pancreatic cancer. Aims: To determine the maximum tolerated dose (MTD) of CPI- 613 when used in combination with modified FOLFIRINOX. To assess the safety of CPI-613 + modified FOLFIRINOX To obtain preliminary data on efficacy of treatment.
Results
Updated Results as of July, 2017 Toxicity: No deaths due to adverse events were reported. The MTD was identified at 500 mg/m2 and a total of 18 patients were treated at the MTD. The most common grade 3–4 non-hematological adverse events: hyperglycemia, hypokalemia, peripheral sensory neuropathy, diarrhea, and abdominal pain. The most common grade 3–4 hematological adverse events: neutropenia, lymphopenia, anemia and thrombocytopenia Preliminary efficacy: Of the 18 patients treated at MTD– 8 patients are alive and 3 patients are still on treatment. The median PFS is 10.4 months, 95% CI (119 to 560 days) – 3 patients are still alive and on treatment who have not progressed. Median overall survival is 20.1 months, data still maturing. The 95% CI cannot be accurately estimated yet. Three patients achieved a complete response.
Conclusions
CPI-613 is a first in class non-redox active lipoate derivative being tested in phase I clinical trial in combination with FOLFIRINOX. The MTD for CPI-613 was identified at 500mg/m2. The treatment combination is feasible and well-tolerated. The response rate was 61%, which is higher than FOLFIRINOX alone (31.6%). The median PFS is 10.4months and the median OS is 20.1 months, data still maturing. A randomized, international phase 3 study of FOLFIRINOX vs. m FOLFIRINOX+ CPI613 will open in 2018.
Clinical trial identification
NCT01835041, First received: April 16, 2013 Last updated: May 30, 2017 Last verified: May 2017
Legal entity responsible for the study
Wake Forest University, School of Medicine
Funding
Cornerstone Pharmaceutical now Rafael Pharmaceuticals
Disclosure
T. Pardee: Chief Medical Officer and employee of Rafael Pharmaceutical (name change on June 5th 2017 from Cornerstone Pharmaceutical). Dr Pardee has no stock or equity in the company. S. Luther: Employee of Rafael Pharmaceuticals and the COO of the company. He owns stock in the company. All other authors have declared no conflicts of interest.